April 23, 2020 / 2:48 PM / a month ago

BRIEF-Innovent Biologics Says Revenue Attributable To Sales Of Tyvyt (Sintilimab Injection) In Q1 Around Rmb400 Million

April 23 (Reuters) - Innovent Biologics Inc:

* REVENUE ATTRIBUTABLE TO SALES OF TYVYT (SINTILIMAB INJECTION) IN Q1 AROUND RMB400 MILLION Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below